AGP Limited AGP Limited operates as an independent pharmaceutical manufacturing company in Pakistan and Afghanistan. The company offers products in the areas of aminoglycosides, angiotensin II antagonist, anti-epileptics, anti-gout, anti-infective antidiarrheal, anti-inflammatory enzyme, antidiarrheal microorganisms, antifibrinolytic, antihistamines systemic, antileuk anti-ashtm sys, antineoplastic agent, anti-obesity, antirheumatic non-steroid, antispasmodic and anticholinergic plain, atypical antipsychotics, biguanide and S-urea combs, and bile stone the... [
AGP — AGP Limited
Sector: Pharmaceuticals · Pakistan Stock Exchange
⚠ Prices: 6 Nov 2026 — PSX end-of-day close (feed fetched 23:14 PKT) · Fundamentals: public data collected 6 Nov 2026 · Not live prices.Summary — AGP
| Measure | Value |
|---|---|
| Price (Rs, 6 Nov — PSX delayed feed) | 153.51 |
| Change, 6 Nov session (delayed) | -1.58% |
| Volume (shares, 6 Nov session) | 46,255 |
| Market capitalisation | Rs 42.78 bn |
| Revenue (TTM) | Rs 26.52 bn |
| Price / Earnings (P/E) | 11.00 |
| Price / Book (P/B) | 2.75 |
| Dividend yield | 5.40% |
| Return on equity (ROE) | 25.90% |
| Net margin | 15.00% |
| Debt / Equity (as reported by source) | 59.10% |
| Revenue growth, 3-year | 26.00% |
Company Snapshot
| Paid-up Capital | Rs 2,800.00 mn |
| Authorized Capital | Rs 3,500.00 mn |
| Shares Outstanding | 280.00 mn |
| Free Float | 84.00 mn |
| Free Float % | 30.0 % |
| Face Value | Rs 10.00 |
| Fiscal Year End | December |
| Avg Volume (12M) | 520,503 |
| Book Value / Share | Rs. 42.39 (Upto 2026 2Q) |
| Total Book Value (computed) | Rs 11.87 bn |
Capital data: SCSTRADE company snapshot, collected 6 Nov 2026. Total Book Value is computed on this page as Book Value / Share × Shares Outstanding.
PSX Scorecard — five checks on this stock's own data
VALUE
6/6
FUTURE
1/6
PAST
6/6
HEALTH
5.5/6
DIVIDEND
5.5/6
Strongest: Value (6/6). Weakest: Future growth (1/6).
How this is scored
Scores are computed mechanically from the data on this page, 0–6 per axis, scaled over the checks that could be run — an axis with no data is labelled, never scored zero for missing data. VALUE: upside to the average analyst target (bands from +30% down), P/E and P/B below the sector median, yield above the sector median. FUTURE: S&P consensus forward EPS and revenue growth bands (only where estimates exist). PAST: revenue and EPS growth across the published financial history, latest year profitable, ROE bands. HEALTH: debt/equity bands, positive latest net margin, no loss-making year in the history. DIVIDEND: yield bands, years of recorded DPS, DPS trend, and payout (DPS ÷ EPS) at or under 100%. The full rule table is in the site's data inventory. Scores are a data summary, not a recommendation.
Performance — AGP
1W+4.1%
1M+3.9%
3M-18.7%
6M-16.4%
1Y-19.0%
Returns computed from daily closes to 05 Nov 2026 (Yahoo Finance PSX series, collected 6 Nov 2026); each bar is scaled to the largest move shown.
52-week range — daily-close series
52-week lowRs 147.29Now Rs 153.51
+4.2% above low · −36.9% below high52-week highRs 243.29
+4.2% above low · −36.9% below high52-week highRs 243.29
Day range — 6 Nov 2026 session
Day lowRs 151.00Close Rs 153.51Day highRs 155.98
Day high/low from the official PSX market-summary feed for the 6 Nov 2026 session.
Investment Case — AGP
Average analyst target vs current price
Average target Rs 237.60 vs current price Rs 153.51 — +54.8% upside to the average target.
Average of 1 target (StockAnalysis consensus), latest per house. This is the named analysts' average, not a PSX Analysis fair-value estimate.
Strengths — from the numbers
- Revenue grew +210.1% across the published history, FY2021–FY2025 (Rs 9,317m → Rs 28,890m).
- Earnings per share grew +113.8% across the published history, FY2021–FY2025 (Rs 6.24 → Rs 13.34).
- Return on equity of 25.90% on the dataset's trailing figures.
- Debt/equity of 0.59 — below 1 (the source reports this figure as 59.10%).
- Dividends recorded in every one of the 5 years in the published record; latest DPS Rs 8.00 (2025), a dividend yield of 5.40% at the current price.
Risks / watch points — from the numbers
- Net margin has fallen to 12.93% in FY2025, from 18.75% in FY2021.
- Share price is down -19.0% over the past year on the chart series (2025-11-06 → 2026-11-05).
Recent performance — FY2025
| Revenue | Rs 28,890m (+15.4% vs FY2024) |
| Net income | Rs 3,735m (+39.9% vs FY2024) |
| EPS | Rs 13.34 (+40.0% vs FY2024) |
| Net margin | 12.93% |
Latest published fiscal year from the financial history below (StockAnalysis figures, collected 6 Nov 2026).
Generated from the figures above — PSX Analysis data summary, not investment advice.
Upcoming Result — Broker Forecasts
| House | Result period | Expected EPS | Expected dividend / share | Expected profit | Preview date |
|---|---|---|---|---|---|
| Intermarket Securities | 3QCY26 | Rs 3.03 | none expected | — | 15 Oct 2026 |
Source: Pakistan Market: IMS Universe Earnings Previews - Jul-Sep 2026. Collected 6 Nov 2026.
Expected Dividend — Broker Estimate
| House | Expected dividend / share | Expected yield |
|---|---|---|
| SCSTRADE (Standard Capital Securities) | Rs 5.38 | 3.50% |
House's published expected dividend, Upto 2026 3Q — SCSTRADE company snapshot, collected 7 Nov 2026.
Forecasts are the publishing houses' own estimates — not actual results and not PSX Analysis estimates.
Quotes — AGP
| Quote | Value |
|---|---|
| Last price (Rs) | 153.51 |
| Change, 6 Nov session | -1.58% |
| Day open, 6 Nov (Rs) | 155.98 |
| Day high, 6 Nov (Rs) | 155.98 |
| Day low, 6 Nov (Rs) | 151.00 |
| Previous close — LDCP (Rs) | 155.98 |
| Volume (shares, 6 Nov session) | 46,255 |
| Market capitalisation | Rs 42.78 bn |
| 1-year high (chart series, Rs) | 243.29 |
| 1-year low (chart series, Rs) | 147.29 |
| 1-year change (chart series) | -19.0% |
Day open/high/low and previous close (LDCP) are from the official PSX market-summary feed for the 6 Nov 2026 session, the same feed that supplies the closing price. 1-year figures are computed from the daily-close chart series below.
Last 10 trading sessions
| Date | Close (Rs) | Change |
|---|---|---|
| 05 Nov 2026 | 155.98 | +2.90% |
| 04 Nov 2026 | 151.58 | +2.91% |
| 03 Nov 2026 | 147.29 | -0.76% |
| 02 Nov 2026 | 148.42 | +0.20% |
| 30 Oct 2026 | 148.12 | -1.15% |
| 29 Oct 2026 | 149.85 | -0.94% |
| 28 Oct 2026 | 151.27 | +0.00% |
| 27 Oct 2026 | 151.27 | -0.88% |
| 26 Oct 2026 | 152.62 | -1.96% |
| 23 Oct 2026 | 155.67 | -0.92% |
Daily closes: Yahoo Finance PSX series, collected 6 Nov 2026. The series records closes only, so no volume column is shown.
Technical Chart — AGP
Loading chart…
Daily candles — Yahoo Finance daily data to 6 Nov 2026 · End-of-day, delayed — not real-time prices.
2024-11-06 → 2026-11-06 · +7.8% over the period · 514 trading days · Moving averages, RSI and MACD are computed in your browser from the same daily bars. Trend lines connect the two most recent swing highs/lows.
1-year returns compared
| 1-year price change | Change |
|---|---|
| AGP (this stock) | -19.0% |
| Sector median — Pharmaceuticals (median of 12 stocks in our dataset) | -13.0% |
| All listed stocks median (median of 440 stocks in our dataset) | -6.2% |
Price change only (dividends not included), from the daily-close series above.
Technicals — AGP
Moving averages
| Average | Value (Rs) | Price vs average |
|---|---|---|
| MA20 — 20-session average | 155.63 | Price Below |
| MA50 — 50-session average | 156.90 | Price Below |
| MA200 — 200-session average | 185.65 | Price Below |
RSI (14) — 51.0 · Neutral
030 — oversold below70 — overbought above100
Wilder RSI(14) computed from the daily-close series. RSI is a momentum gauge, not a buy or sell signal.
Classic pivot levels — from the 6 Nov session
| Level | Rs |
|---|---|
| Resistance 2 (R2) | 158.48 |
| Resistance 1 (R1) | 155.99 |
| Pivot point (PP) | 153.50 |
| Support 1 (S1) | 151.01 |
| Support 2 (S2) | 148.52 |
Classic pivots from the 6 Nov 2026 session's high (Rs 155.98), low (Rs 151.00) and close (Rs 153.51) in the official PSX feed. The close sits above the pivot point.
Signals summary
| Reading | Status |
|---|---|
| Price vs MA20 | Below |
| Price vs MA50 | Below |
| Price vs MA200 | Below |
| RSI (14) zone | Neutral (51.0) |
| MACD vs signal line | Below |
| Short-term trend (MA20 vs MA50) | Down |
| Medium-term trend (MA50 vs MA200) | Down |
| Long-term trend (price vs MA200) | Down |
Trend labels compare the named averages (long-term compares the price with MA200); “Up” means the first-named sits above the second. Mechanical readings from daily closes — not investment advice.
Technicals are mechanical calculations on past prices. Based on daily closes to 05 Nov 2026. They describe momentum and recent trading ranges only — not investment advice.
Company — AGP
| Company | AGP Limited |
| Symbol | AGP |
| Sector | Pharmaceuticals |
| Market capitalisation | Rs 42.78 bn |
| Revenue (TTM) | Rs 26.52 bn |
Founded 1989 · Employees 2,143 — as published by StockAnalysis.
Company description: StockAnalysis company profile, collected 6 Nov 2026.
Exchange record: PSX company profile for AGP (Pakistan Stock Exchange data portal).
Financials — AGP
Revenue (TTM)
Rs 26,523m
Rs 26,523m
Net income (TTM)
Rs 3,545m
Rs 3,545m
EPS (TTM)
Rs 13.49
Rs 13.49
Net margin (TTM)
13.37%
13.37%
P/E
11.00
11.00
P/B
2.75
2.75
Dividend yield
5.40%
5.40%
ROE
25.90%
25.90%
Net margin
15.00%
15.00%
Debt / Equity
59.10%
59.10%
| Measure | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 F |
|---|---|---|---|---|---|---|
| Revenue (Rs m) | 9,317 | 14,459 | 18,743 | 25,034 | 28,890 | 31,760 |
| Operating income (Rs m) | 2,470 | 2,969 | 4,285 | 7,040 | 8,020 | — |
| Net income (Rs m) | 1,747 | 1,570 | 1,565 | 2,670 | 3,735 | — |
| EPS (Rs) | 6.24 | 5.61 | 5.59 | 9.53 | 13.34 | 10.80 |
| Net margin | 18.75% | 10.86% | 8.35% | 10.66% | 12.93% | — |
| Dividend per share (Rs) | 2.50 | 2.00 | 2.50 | 4.00 | 8.00 | 5.00 |
Trailing twelve months (to Sep 30, 2026, not a completed fiscal year): Revenue Rs 26,523m · Net income Rs 3,545m · EPS Rs 13.49 · Net margin 13.37%.
Source: StockAnalysis financials, collected 6 Nov 2026 — this stock's published history here spans FY2021–FY2025 (5 fiscal years; the source table publishes a maximum of five completed years per stock). A dash means the source did not publish that figure for that year.
F = analyst consensus forecast — S&P Global estimates via StockAnalysis, collected 7 Nov 2026. Forecasts are estimates, not results. The source publishes forecast revenue, EPS and dividend per share only — no forecast operating income, net income or margin — so those cells are dashed.
Dividend History
| Dividend per share (Rs, per fiscal year) | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| DPS | 2.5 | 2 | 2.5 | 4 | 8 |
A dash means no dividend was recorded for that year in the source. Source: StockAnalysis dividend history, collected 6 Nov 2026.
All recorded dividend payments
Payments recorded since 2022 — StockAnalysis, collected 7 Nov 2026.
| Ex-dividend date | Dividend (Rs) | Pay date |
|---|---|---|
| Sep 2, 2026 | 2.000 | Sep 9, 2026 |
| Apr 13, 2026 | 6.000 | Apr 21, 2026 |
| Sep 2, 2025 | 2.000 | Sep 11, 2025 |
| Mar 27, 2025 | 4.000 | Apr 11, 2025 |
| Mar 8, 2024 | 2.500 | Mar 21, 2024 |
| Apr 10, 2023 | 2.000 | Apr 20, 2023 |
| Apr 15, 2022 | 2.500 | Apr 28, 2022 |
Payout ratio, FY2025: dividend per share Rs 8.00 ÷ EPS Rs 13.34 = 60.0% of earnings paid out as dividends.
Valuation & Fair Value — AGP
Broker Fair Value — average target price
Rs 237.60
Current price Rs 153.51 · +54.8% · verdict on the target-upside bands: Undervalued
Average of 1 target price (0 broker houses + StockAnalysis consensus), range Rs 237.60–237.60. See the Target Prices page for houses and dates. Targets are the houses' own estimates.
Fair P/E Value — sector multiple
Rs 165.93
Current price Rs 153.51 · +8.1%
Formula: sector median P/E 12.30× × EPS Rs 13.49 = Rs 165.93. Sector median across 12 Pharmaceuticals peers with a published P/E — the same basis as the median table below. EPS is the trailing-twelve-month (TTM) figure published in the dataset.
Fair P/B Value — sector multiple
Rs 124.63
Current price Rs 153.51 · -18.8%
Formula: sector median P/B 2.94× × book value per share Rs 42.39 = Rs 124.63. Sector median across 11 Pharmaceuticals peers with a published P/B — the same basis as the median table below. Book value per share from the SCSTRADE company snapshot (Upto 2026 2Q), collected 6 Nov 2026.
2 of 3 measures above the current price. Each measure stands on its own stated basis — they are deliberately not blended into a single fair value. Mechanical estimates computed from published data; not investment advice.
| Measure | AGP | Sector median |
|---|---|---|
| Price / Earnings (P/E) | 11.00 | 12.30 |
| Price / Book (P/B) | 2.75 | 2.94 |
| Dividend yield | 5.40% | 1.50% |
| Return on equity (ROE) | 25.90% | 21.65% |
Sector median across 14 listed peers in our dataset (sector: Pharmaceuticals), computed only from peers where the measure is published; a median is shown only when at least 5 peers have the measure.
Consensus — AGP
Analyst Forecasts — StockAnalysis / S&P Global consensus
Consensus rating: Buy · 4 analysts polled by S&P Global · Consensus price target: Rs 237.60 (range Rs 217.80 – Rs 275.00)
| Analyst estimate | FY2026 (E) |
|---|---|
| Revenue estimate (Rs m) | 31,760 |
| EPS estimate (Rs) | 10.80 |
| Dividend estimate (Rs/share) | 5.00 |
Analyst estimates — not our forecasts. This is the international S&P Global consensus republished by StockAnalysis (collected 7 Nov 2026); it is a different source from the Pakistani broker-house targets on the Broker Target Prices page. (E) = estimated future fiscal year.
Ratings — AGP
S&P Global consensus rating (via StockAnalysis): Buy — from 4 analysts.
Calendar — AGP
| Ex-dividend date | Dividend (Rs) | Pay date | Status |
|---|---|---|---|
| Sep 2, 2026 | 2.000 | Sep 9, 2026 | Paid |
| Apr 13, 2026 | 6.000 | Apr 21, 2026 | Paid |
| Sep 2, 2025 | 2.000 | Sep 11, 2025 | Paid |
| Mar 27, 2025 | 4.000 | Apr 11, 2025 | Paid |
| Mar 8, 2024 | 2.500 | Mar 21, 2024 | Paid |
| Apr 10, 2023 | 2.000 | Apr 20, 2023 | Paid |
| Apr 15, 2022 | 2.500 | Apr 28, 2022 | Paid |
Dividend dates as recorded by StockAnalysis (collected 6 Nov 2026); past payments are labelled Paid. Market-closed days that affect settlement: PSX Holidays 2026 · more yields and payers on the dividend hub.
Sector — AGP
AGP ranks #6 by market capitalisation among the 14 listed Pharmaceuticals stocks in our dataset. Full sector tables: Sectors.
FAQ — AGP
What is the current AGP share price?
AGP Limited (AGP) last traded at Rs 153.51 in the 6 Nov 2026 session, -1.58% on the day. Prices on this page are the PSX end-of-day close from the official delayed feed, not live prices.
What is AGP's 52-week range?
Across the daily-close series (2025-11-06 to 2026-11-05), AGP traded between Rs 147.29 and Rs 243.29. The latest close in the series was Rs 155.98.
Which PSX sector is AGP in?
AGP Limited (AGP) is classified in the Pharmaceuticals sector on the Pakistan Stock Exchange.
What is the latest AGP dividend?
Total dividend per share for fiscal 2025 was Rs 8.00; the most recent recorded payment is Rs 2.00 per share (ex-date Sep 2, 2026, pay date Sep 9, 2026). Dividend history as recorded by StockAnalysis, collected 6 Nov 2026.
What are AGP's P/E ratio and dividend yield?
AGP Limited (AGP) shows a P/E ratio of 11.00 and a dividend yield of 5.40% in the public data collected 6 Nov 2026.
Answers are generated from this page's own figures (public data collected 6 Nov 2026; prices are the 6 Nov 2026 PSX end-of-day close, not live).
AGP Limited (AGP) is classified in the Pharmaceuticals sector on the Pakistan Stock Exchange.
Every figure above comes from public listings collected on 6 November 2026 (StockAnalysis and SmartMoney, merged by symbol), with the price, change and volume refreshed on 6 Nov 2026 from the official PSX delayed market feed (end-of-day close, fetched 23:14 PKT) — delayed figures, not live prices. If this stock was absent from that feed, its price is the previous latest close. A dash means the measure was not published for this stock by the sources, not that it is zero. Compare AGP with the market's largest shares in the Top 250 screener, browse the whole market in Stocks A–Z, and read the ratios explainer in Learn.
This page is a data summary for education, not a recommendation to buy or sell AGP.